Pluristem's Promising GvHD Indication Pits It Against Osiris
Investors Are Bailing Because Pluristem Owns The Space ! Happy Halloween !
Investors in biotechnology should question why Osiris is trading at a market cap of $642 million and Pluristem at slightly under $200 million. Pluristem's platform technology supports a much fuller pipeline and may soon encroach on Osiris' hopeful GvHD franchise. Also separating Pluristem from Osiris and other cell therapy companies is its manufacturing prowess. Independent researchers have recognized in scientific journals that placental cells of the kind Pluristem processes (mesenchymal) are best done in a bioreactor with appropriate quality control for a large and consistent yield. Harvesting of mesenchymal cells can be performed at the laboratory level, but no one yet has been able to translate the technology to an industrial scale. This is Pluristem's core competitive angle, ready to be exploited.